Gilead Sciences, Inc.
corporate_fare Company Profile
Gilead Sciences, Inc. (NASDAQ:GILD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for GILD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for GILD spans 8-K.
Recent high-impact activity:
- Lenacapavir Doubles One-Year PrEP Persistence vs Daily Pills in PURPOSE 5
- Livdelzi Hits 75.4% ALP Normalization at Week 52 in Phase 3 PBC Study
- Gilead Q3 Beats, Lifts 2026 Sales Guidance to $31.0-31.3B, but Loss Outlook Widens
- Gilead Posts 3Q EPS of $1.94
- $1.275B Upfront Deal Adds Oral IL-23R Inhibitor to Gilead's IBD Pipeline
Financial Snapshot
Short Interest & Short Volume
3.18 days to coverFINRA reported short interest of 21,271,970 shares in GILD as of the October 30, 2026 settlement, a 4.9% increase from the prior period — about 3.2 days to cover at its recent average daily volume. On November 20, 2026, 50.7% of GILD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for GILD, detected from its recent SEC filings.
New Shelf Registration Filed · No Immediate Offering
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →